Executive committee

Pr François ROMAGNÉ

Scientific Director

Professor of immunotechnology at Aix-Marseille University (AMU) and co-founder of Innate Pharma, François Romagné contributed to the creation of MI-mAbs, where he has been the Scientific Director since January 1, 2014.

He brings his knowledge and his experience of antibodies, both from the diagnostics side (14 years spent within the immunodiagnostic company Immunotech) and therapeutic applications (14 years as Chief Scientific Officer of Innate Pharma of whom he is now members of Scientific Advisory Board).

François is the author of over 50 scientific publications and 15 patents.

Dr Stéphanie BLANCHIN

Head of the antibody group

Dr. Stéphanie Blanchin boasts a long experience in development and characterization of monoclonal antibodies for diagnostic (CHU de Caen) as well as therapeutic (PX'Therapeutics) purposes.

Holding a PhD in Immunology from Aix-Marseille Université (AMU), Stéphanie Blanchin joined the laboratory of Immunology and immunopathology of the CHU of Caen at the end of her postdoctoral internship in the Department of Medical Biochemistry, Cardiff University.

This first experience led to the generation of therapeutic monoclonal antibodies for the biotechnology society PXTherapeutics prior to joining MI-mAbs in September 2013.

Dr Laurent POUYET

Head of the Immuno-Pharmacology group

Head of the Immuno-Pharmacology group, Laurent POUYET has a long experience of in vitro and in vivo models to characterize the efficacy and toxicity of drug candidates in cancer and inflammatory diseases.

Holding a Doctorate in Immunology from Aix-Marseille Université (AMU) at the Marseille-Luminy Immunology Center (CIML) in the team of Professor Philippe NAQUET, Laurent POUYET pursued two postdoctoral fellowships in the teams of Professor Gerard Evan from the University of California San Francisco (UCSF) and Dr. Alice Carrier from the Marseille Cancer Research Center (CRCM) where he developed and used many models to mimic and better understand the biological mechanisms involved in Cancer and inflammatory diseases.

Building on this experience, Laurent worked at TrGET, the pre-clinical assay platform of the Paoli-Calmettes Institute (IPC) before joining MI-mAbs in April 2014.